2023
The Representation of Surgery in Oncology Clinical Trials: 2001 to 2022
Shah R, Boffa D, Khan S, Judson B. The Representation of Surgery in Oncology Clinical Trials: 2001 to 2022. Annals Of Surgical Oncology 2023, 30: 7275-7280. PMID: 37556010, DOI: 10.1245/s10434-023-14064-4.Peer-Reviewed Original Research
2022
Cancer of the Lung
Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Ko J, Soto L, Waqar S, Wistuba I, Herbst R. Cancer of the Lung. 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.Peer-Reviewed Original Research
2020
Surgeon's Perspective to Local Therapy in Oligometastatic Cancer.
Boffa DJ. Surgeon's Perspective to Local Therapy in Oligometastatic Cancer. The Cancer Journal 2020, 26: 149-155. PMID: 32205540, DOI: 10.1097/ppo.0000000000000441.Peer-Reviewed Original Research
2018
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Goodman K, Hall N, Bekaii-Saab T, Ou F, Twohy E, Meyers M, Boffa D, Mitchell K, Perry K, Frankel W, Venook A, O'Reilly E, Ilson D. Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. Journal Of Clinical Oncology 2018, 36: 4012-4012. DOI: 10.1200/jco.2018.36.15_suppl.4012.Peer-Reviewed Original Research
2017
Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians. Surgery 2017, 162: 640-651. PMID: 28697883, DOI: 10.1016/j.surg.2017.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDatabases, FactualDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyProportional Hazards ModelsRadiotherapyRegistriesRisk AssessmentSecondary PreventionSurvival AnalysisConceptsCell lung cancerLocal therapyLung cancerStage IRelative survivalStereotactic body radiation therapyNational Cancer DatabaseBetter overall survivalBody radiation therapyOlder patientsOverall survivalPatient ageYounger patientsOverall mortalityPrimary outcomeCancer DatabaseTreatment outcomesTreatment decisionsRadiation therapyPatientsTherapyCancerNonagenariansTreatmentSurvival